Effects of insulin therapy optimization with sensor augmented pumps on glycemic control and body composition in people with cystic fibrosis-related diabetes
ObjectiveCystic fibrosis (CF)-related diabetes (CFRD) resulting from partial-to-complete insulin deficiency occurs in 40-50% of adults with CF. In people with CFRD, poor glycemic control leads to a catabolic state that may aggravate CF-induced nutritional impairment and loss of muscle mass. Sensor a...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-08-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1228153/full |
| _version_ | 1797730244210196480 |
|---|---|
| author | V. Grancini G. Alicandro G. Alicandro L. L. Porcaro L. Zazzeron A. Gramegna A. Gramegna L. C. Morlacchi V. Rossetti A. Gaglio V. Resi V. Daccò F. Blasi F. Blasi E. Orsi |
| author_facet | V. Grancini G. Alicandro G. Alicandro L. L. Porcaro L. Zazzeron A. Gramegna A. Gramegna L. C. Morlacchi V. Rossetti A. Gaglio V. Resi V. Daccò F. Blasi F. Blasi E. Orsi |
| author_sort | V. Grancini |
| collection | DOAJ |
| description | ObjectiveCystic fibrosis (CF)-related diabetes (CFRD) resulting from partial-to-complete insulin deficiency occurs in 40-50% of adults with CF. In people with CFRD, poor glycemic control leads to a catabolic state that may aggravate CF-induced nutritional impairment and loss of muscle mass. Sensor augmented pump (SAP) therapy may improve glycemic control as compared to multiple daily injection (MDI) therapy.Research design and methodsThis non-randomized clinical trial was aimed at evaluating the effects of insulin therapy optimization with SAP therapy, combined with a structured educational program, on glycemic control and body composition in individuals with insulin-requiring CFRD. Of 46 participants who were offered to switch from MDI to SAP therapy, 20 accepted and 26 continued the MDI therapy. Baseline demographic and clinical characteristics were balanced between groups using a propensity score-based overlap weighting procedure and weighted mixed-effects regression models were used to estimate changes in study outcomes.ResultsAfter 24 months changes in HbA1c were: -1.1% (-12.1 mmol/mol) (95% CI: -1.5; -0.8) and -0.1% (-1 mmol/mol) (95% CI: -0.5; 0.3) in the SAP and MDI therapy group, respectively, with a between-group difference of -1.0 (-10 mmol/mol) (-1.5; -0.5). SAP therapy was also associated with a decrease in mean glucose (between group difference: -32 mg/dL; 95% CI: -44; -20) and an increase in TIR (between group difference: 19.3%; 95% CI 13.9; 24.7) and in fat-free mass (between group difference: +5.5 Kg, 95% CI: 3.2; 7.8).ConclusionTherapy optimization with SAP led to a significant improvement in glycemic control, which was associated with an increase in fat-free mass. |
| first_indexed | 2024-03-12T11:41:27Z |
| format | Article |
| id | doaj.art-4093080159ef47a2a2d526830534ab28 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-03-12T11:41:27Z |
| publishDate | 2023-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-4093080159ef47a2a2d526830534ab282023-08-31T14:54:49ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922023-08-011410.3389/fendo.2023.12281531228153Effects of insulin therapy optimization with sensor augmented pumps on glycemic control and body composition in people with cystic fibrosis-related diabetesV. Grancini0G. Alicandro1G. Alicandro2L. L. Porcaro3L. Zazzeron4A. Gramegna5A. Gramegna6L. C. Morlacchi7V. Rossetti8A. Gaglio9V. Resi10V. Daccò11F. Blasi12F. Blasi13E. Orsi14Diabetes Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDepartment of Pathophysiology and Transplantation, University of Milan, Milan, ItalyPediatrics, Gastroenterology, Hepatology, Pediatric Transplantation and Cystic Fibrosis Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDiabetes Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyPediatrics, Gastroenterology, Hepatology, Pediatric Transplantation and Cystic Fibrosis Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDepartment of Pathophysiology and Transplantation, University of Milan, Milan, ItalyRespiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyRespiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyRespiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDiabetes Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDiabetes Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyPediatrics, Gastroenterology, Hepatology, Pediatric Transplantation and Cystic Fibrosis Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDepartment of Pathophysiology and Transplantation, University of Milan, Milan, ItalyRespiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDiabetes Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyObjectiveCystic fibrosis (CF)-related diabetes (CFRD) resulting from partial-to-complete insulin deficiency occurs in 40-50% of adults with CF. In people with CFRD, poor glycemic control leads to a catabolic state that may aggravate CF-induced nutritional impairment and loss of muscle mass. Sensor augmented pump (SAP) therapy may improve glycemic control as compared to multiple daily injection (MDI) therapy.Research design and methodsThis non-randomized clinical trial was aimed at evaluating the effects of insulin therapy optimization with SAP therapy, combined with a structured educational program, on glycemic control and body composition in individuals with insulin-requiring CFRD. Of 46 participants who were offered to switch from MDI to SAP therapy, 20 accepted and 26 continued the MDI therapy. Baseline demographic and clinical characteristics were balanced between groups using a propensity score-based overlap weighting procedure and weighted mixed-effects regression models were used to estimate changes in study outcomes.ResultsAfter 24 months changes in HbA1c were: -1.1% (-12.1 mmol/mol) (95% CI: -1.5; -0.8) and -0.1% (-1 mmol/mol) (95% CI: -0.5; 0.3) in the SAP and MDI therapy group, respectively, with a between-group difference of -1.0 (-10 mmol/mol) (-1.5; -0.5). SAP therapy was also associated with a decrease in mean glucose (between group difference: -32 mg/dL; 95% CI: -44; -20) and an increase in TIR (between group difference: 19.3%; 95% CI 13.9; 24.7) and in fat-free mass (between group difference: +5.5 Kg, 95% CI: 3.2; 7.8).ConclusionTherapy optimization with SAP led to a significant improvement in glycemic control, which was associated with an increase in fat-free mass.https://www.frontiersin.org/articles/10.3389/fendo.2023.1228153/fullcystic fibrosiscystic fibrosis related diabetessensor augmented pumpsinsulin therapy optimizationinsulin pumpsinsulin |
| spellingShingle | V. Grancini G. Alicandro G. Alicandro L. L. Porcaro L. Zazzeron A. Gramegna A. Gramegna L. C. Morlacchi V. Rossetti A. Gaglio V. Resi V. Daccò F. Blasi F. Blasi E. Orsi Effects of insulin therapy optimization with sensor augmented pumps on glycemic control and body composition in people with cystic fibrosis-related diabetes Frontiers in Endocrinology cystic fibrosis cystic fibrosis related diabetes sensor augmented pumps insulin therapy optimization insulin pumps insulin |
| title | Effects of insulin therapy optimization with sensor augmented pumps on glycemic control and body composition in people with cystic fibrosis-related diabetes |
| title_full | Effects of insulin therapy optimization with sensor augmented pumps on glycemic control and body composition in people with cystic fibrosis-related diabetes |
| title_fullStr | Effects of insulin therapy optimization with sensor augmented pumps on glycemic control and body composition in people with cystic fibrosis-related diabetes |
| title_full_unstemmed | Effects of insulin therapy optimization with sensor augmented pumps on glycemic control and body composition in people with cystic fibrosis-related diabetes |
| title_short | Effects of insulin therapy optimization with sensor augmented pumps on glycemic control and body composition in people with cystic fibrosis-related diabetes |
| title_sort | effects of insulin therapy optimization with sensor augmented pumps on glycemic control and body composition in people with cystic fibrosis related diabetes |
| topic | cystic fibrosis cystic fibrosis related diabetes sensor augmented pumps insulin therapy optimization insulin pumps insulin |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2023.1228153/full |
| work_keys_str_mv | AT vgrancini effectsofinsulintherapyoptimizationwithsensoraugmentedpumpsonglycemiccontrolandbodycompositioninpeoplewithcysticfibrosisrelateddiabetes AT galicandro effectsofinsulintherapyoptimizationwithsensoraugmentedpumpsonglycemiccontrolandbodycompositioninpeoplewithcysticfibrosisrelateddiabetes AT galicandro effectsofinsulintherapyoptimizationwithsensoraugmentedpumpsonglycemiccontrolandbodycompositioninpeoplewithcysticfibrosisrelateddiabetes AT llporcaro effectsofinsulintherapyoptimizationwithsensoraugmentedpumpsonglycemiccontrolandbodycompositioninpeoplewithcysticfibrosisrelateddiabetes AT lzazzeron effectsofinsulintherapyoptimizationwithsensoraugmentedpumpsonglycemiccontrolandbodycompositioninpeoplewithcysticfibrosisrelateddiabetes AT agramegna effectsofinsulintherapyoptimizationwithsensoraugmentedpumpsonglycemiccontrolandbodycompositioninpeoplewithcysticfibrosisrelateddiabetes AT agramegna effectsofinsulintherapyoptimizationwithsensoraugmentedpumpsonglycemiccontrolandbodycompositioninpeoplewithcysticfibrosisrelateddiabetes AT lcmorlacchi effectsofinsulintherapyoptimizationwithsensoraugmentedpumpsonglycemiccontrolandbodycompositioninpeoplewithcysticfibrosisrelateddiabetes AT vrossetti effectsofinsulintherapyoptimizationwithsensoraugmentedpumpsonglycemiccontrolandbodycompositioninpeoplewithcysticfibrosisrelateddiabetes AT agaglio effectsofinsulintherapyoptimizationwithsensoraugmentedpumpsonglycemiccontrolandbodycompositioninpeoplewithcysticfibrosisrelateddiabetes AT vresi effectsofinsulintherapyoptimizationwithsensoraugmentedpumpsonglycemiccontrolandbodycompositioninpeoplewithcysticfibrosisrelateddiabetes AT vdacco effectsofinsulintherapyoptimizationwithsensoraugmentedpumpsonglycemiccontrolandbodycompositioninpeoplewithcysticfibrosisrelateddiabetes AT fblasi effectsofinsulintherapyoptimizationwithsensoraugmentedpumpsonglycemiccontrolandbodycompositioninpeoplewithcysticfibrosisrelateddiabetes AT fblasi effectsofinsulintherapyoptimizationwithsensoraugmentedpumpsonglycemiccontrolandbodycompositioninpeoplewithcysticfibrosisrelateddiabetes AT eorsi effectsofinsulintherapyoptimizationwithsensoraugmentedpumpsonglycemiccontrolandbodycompositioninpeoplewithcysticfibrosisrelateddiabetes |